Morepen Lab

delhi, India


“Enhanced focus on cost reduction and adoption of innovative processes resulted in this remarkable turnaround, putting the company back on the profit trajectory,” Mr. Suri said. Q4 marked excellent performance in all business segments particularly bulk drugs (API) which has grown by more than 50%, while Home Diagnostics and Finished Dosages segments also outperformed and registered a remarkable growth of 35% and 40% respectively adding to the outstanding quarterly performance.

Joined: 28/02/2018


Presentations: ..

Podcasts: ..

Favorite: ..

Subscribe to author's: Rss


Yet to create a Channel

Subscribed Channels

Yet to subscribe to a Channel

Followers ..

No followers yet

Morepen Lab's PowerPoint Presentations

Recent Activity

No recent activity
authorStream Live Help